Skip to main content
. 2010 May 26;2010:178372. doi: 10.1155/2010/178372

Table 2.

Indications, limitations and contraindications of CSII in diabetic patients.

Long-term indications
When clear proven benefit over MDI
is proven and when other intensified
insulin regimens fail to achieve
adequate glycaemic control.
Short-term indications Contradictions
(1) Elevated HbA1c with MDI therapy
(2) Marked same-day or between-day glucose
levels fluctuations
(3) Variability of insulin requirements
 (i) Endogenous causes: dawn phenomenon
 (ii) Exogenous causes: work type
particuliarities (e.g., shift workers or
business travellers)
(4) Recurrent hypoglycaemia (severe or
non-severe)
 (i) Failure to maintain HbA1c targets
(<7.0%) without the occurrence of
disabling or frequent symptomatic or
asymptomatic hypoglycaemic events
(≥4/week)
 (ii) Incidence of ≥1 episode(s)/year of
unexplained severe hypoglycaemia
(5) Other reasons:
 (i) Allergy to insulin
 (ii) Lipoatrophic diabetes
 (iii) Very low insulin requirements
(1) Acute situations (e.g., in diabetology units):
 (i) For the treatment of mild ketoacidosis
or acute hyperglycaemia
 (ii) For acute infections
 (iii) Undergoing enteral alimentation
(2) Transient situations
 (i) Severe painful neuropathy
 (ii) Chronic infections, foot ulcers and all
wound-healing cicatrization situations
 (iii) Pregnancy or the intention to become
pregnant
(1) Absolute Contradictions
  (i) Severe psychiatric disorders
  (ii) Progressive ischaemic or proliferative
retinopathy
  (iii) Due to the patient's environment or
pump:
  (a) A non-educated medical
environment
  (b) Living with extreme circumstances
of either heat or cold for professional
or personal reasons
  (c) Underwater diving
  (d) Exposure to high electromagnetic
fields (NMR)
(2) Relative Contradictions
 (i) Poor compliance or patient reluctance
to live with the current management
of treatment, (e.g., frequent visits to
diabetology centre, glycaemia
monitoring, ketosis testing)
 (ii) Poor local hygiene and/or
Staphylococcus presence
 (iii) In some cases of end-stage renal
failure because of acidosis risk
attributed to patient incompliance
 (iv) Sensory or gestural impairment
(difficulty with the technical aspects
of pump management)